Key News
1. Tiger International: Starting June 12th, new openings and additional position additions for all instruments held by existing investor accounts in China will be suspended.
Individual Stock News
1. VPower Group (01608.HK): The winding-up petition hearing has been further postponed to August 26th.
2. Agile Group (03383.HK): Pre-sales amounted to approximately RMB 2.98 billion in the first five months, a decrease of 29.72% year-on-year.
3. Yibang Holdings (00599.HK) issued a profit warning: It expects a pre-tax loss of approximately HKD 23 million to HKD 25 million for the year.
4. Everest Medicines (01952.HK) granted Travele an exclusive license to develop and commercialize the new kidney disease drug civorebrutinib, receiving an upfront payment of US$112.5 million. 5. CSPC Pharmaceutical Group (01093.HK)'s first mRNA-LNP-based dual-target CAR-T cell injection (SYS 6063 injection) has received clinical trial approval in China.
6. ZTE Corporation (00763.HK): As of May 31, 2026, the company has repurchased 19,259,100 shares.
